In­nate ends Ph1b in pe­riph­er­al T cell lym­phoma; Lay­offs at NextCure

Plus, news about Evom­mune, Maruho and Nous­com:

In­nate Phar­ma gives up on Phase 1b tri­al for can­cer drug: The com­pa­ny was eval­u­at­ing la­cu­tam­ab as a monother­a­py in KIR3DL2-ex­press­ing re­frac­to­ry/re­laps­ing pe­riph­er­al T cell lym­phoma. In­nate said it’s not plan­ning to restart re­cruit­ment in the tri­al af­ter a clin­i­cal hold was put in­to place for stud­ies as­sess­ing the drug in PT­CL and cu­ta­neous T cell lym­phoma af­ter a pa­tient death was re­port­ed in the lat­ter. It cit­ed a lack of “mean­ing­ful clin­i­cal ac­tiv­i­ty” for la­cu­tam­ab in the PT­CL study eval­u­at­ing the drug as a monother­a­py. It is still be­ing stud­ied in com­bi­na­tion with chemo in a Phase 2 tri­al in PT­CL. — Kather­ine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER